Ashkan Emadi

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells
    Ashkan Emadi
    Johns Hopkins University, School of Medicine, Department of Internal Medicine, Division of Hematology, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Bioorg Med Chem 19:7057-62. 2011
  2. ncbi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
  3. ncbi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
  4. ncbi Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A
    Ashkan Emadi
    Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Hematol 85:264-70. 2010
  5. ncbi Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
  6. ncbi Diagnosis and management of venous thromboembolism: an update a decade into the new millennium
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:341-51. 2011
  7. ncbi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
  8. ncbi Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity
    Ashley E Ross
    Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    BJU Int 108:447-54. 2011
  9. ncbi A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast
    Ashkan Emadi
    Department of Internal Medicine and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 5:e10846. 2010
  10. ncbi Management of acquired thrombophilic disorders in 2011: focus on heparin-induced thrombocytopenia, antiphospholipid syndrome, myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:401-11. 2011

Detail Information

Publications13

  1. ncbi Metabolic and electrochemical mechanisms of dimeric naphthoquinones cytotoxicity in breast cancer cells
    Ashkan Emadi
    Johns Hopkins University, School of Medicine, Department of Internal Medicine, Division of Hematology, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Bioorg Med Chem 19:7057-62. 2011
    ..These results also suggest that dimeric naphthoquinones may be used to selectively target cancer cells that depend on oxidative phosphorylation for energy production and macromolecular synthesis...
  2. ncbi Hematological manifestations of nephropathic cystinosis
    Ashkan Emadi
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Acta Haematol 119:169-72. 2008
    ....
  3. ncbi Cyclophosphamide and cancer: golden anniversary
    Ashkan Emadi
    Division of Adult Hematology, Johns Hopkins University, Baltimore, MD, USA
    Nat Rev Clin Oncol 6:638-47. 2009
    ..We also discuss the development of high-dose cyclophosphamide for BMT and the treatment of autoimmune diseases...
  4. ncbi Analytic validity of genetic tests to identify factor V Leiden and prothrombin G20210A
    Ashkan Emadi
    Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, USA
    Am J Hematol 85:264-70. 2010
    ..There is high-grade evidence that most, but not all, clinical laboratories test for FVL and prothrombin G20210A accurately...
  5. ncbi Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
    ..The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed...
  6. ncbi Diagnosis and management of venous thromboembolism: an update a decade into the new millennium
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:341-51. 2011
    ..The purpose of the current paper is to review the pathogenesis and epidemiology of venous thromboembolism as well as an evidence-based approach to the diagnosis and management of venous thromboembolism...
  7. ncbi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
    ..Testing for genetic risks for venous thromboembolism (VTE) is common, but the safety and utility of such testing need review...
  8. ncbi Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity
    Ashley E Ross
    Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
    BJU Int 108:447-54. 2011
    ..To evaluate the cytotoxicity of dimeric naphthoquinones (BiQs) in prostate cancer cells. • To assess the interaction of dimeric naphthoquinones with common therapies including radiation and docetaxel...
  9. ncbi A chemical genetic screen for modulators of asymmetrical 2,2'-dimeric naphthoquinones cytotoxicity in yeast
    Ashkan Emadi
    Department of Internal Medicine and Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 5:e10846. 2010
    ..In order to gain insight into the mode of action of binaphthoquinones we performed a systematic high-throughput screen in a yeast isogenic deletion mutant array for enhanced or suppressed growth in the presence of binaphthoquinones...
  10. ncbi Management of acquired thrombophilic disorders in 2011: focus on heparin-induced thrombocytopenia, antiphospholipid syndrome, myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria
    Ashkan Emadi
    Division of Hematology, Department of Internal Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
    Arch Iran Med 14:401-11. 2011
    ....
  11. ncbi The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
    Ashkan Emadi
    University of Maryland, School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Leukemia and Hematologic Malignancies, Baltimore, MD 21201, USA
    Pharmacogenomics 13:1257-69. 2012
    ....
  12. ncbi Vitamin and mineral supplements: do we really need them?
    Farin Kamangar
    Department of Public Health Analysis, School of Community Health and Policy, Morgan State University, Baltimore, MD, USA
    Int J Prev Med 3:221-6. 2012
    ..Indeed, some studies have shown increased risk of cancers in relation to using certain vitamins...
  13. ncbi Ruthenium-based chemotherapeutics: are they ready for prime time?
    Emmanuel S Antonarakis
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, CRB1 191, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 66:1-9. 2010
    ....